Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2020)
22 slides from Resonance Health's shareholder meeting presentation, Nov 19, 2020
Slide 1: Resonance Health 2020 AGM Presentation
RESONANCE HEALTH LIMITED (ASX: RHT) For personal use only 2020 AGM PRESENTATION AGM 2020
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Resonance Health Limited only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to
Slide 3: About Resonance Health
ABOUT RESONANCE HEALTH For personal use only To be a global leader developing innovative healthcare products and services, to work diligently to deliver the highest quality products for customers, and to operate with integrity and excellence in driving growth for shareholders. ❖ Resonance Health is
Slide 4: Corporate Snapshot
CORPORATE SNAPSHOT Financial Information (17 November 2020, AUD) Board & Management For personal use only Share Price $0.165 Dr Martin Blake - Non-executive Chairman Number of Shares 444.3m Mr Simon Panton - Non-executive Director 52 Week Range $0.092 - $0.28 Dr Travis Baroni - Non-executive Directo
Slide 5: Performance Snapshot
PERFORMANCE SNAPSHOT For personal use only ❖ Reportable total revenue for FY 2020 was $3.9 million; ❖ NPAT: Excluding non-cash share-based payment expenses for employee and Director options, the Company recorded a positive profit result of $1.1 million for the full year; ❖ Cashflow positive from ope
Slide 6: Diversification Through R&D
DIVERSIFICATION THROUGH R&D For personal use only Research & Development pipeline has three key areas of focus; 1. artificial intelligence (AI); 2. imaging, and; 3. molecular medicine.
Slide 7: R&D: Artificial Intelligence
For personal use only R&D: ARTIFICIAL INTELLIGENCE
Slide 8: FerriSmart
FERRISMART For personal use only At present, Over 330,000 affected infants are born annually (83% sickle cell disorders, 17% thalassaemias). Haemoglobin disorders account for about 3.4% of deaths in children less than 5 years of age1. Sickle cell is an inherited blood disorder that affects 1 to 3 mi
Slide 9: HepaFat-AI
HEPAFAT-AI For personal use only It is estimated that the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is between 24% and 30% of the global population 3, meaning that between 1.8 and 2.3 billion people may currently have NAFLD. Of these, it is estimated that 20%, or up to 468 million, wil
Slide 10: NAFLD clinical trials and HepaFat-AI use
As of February 2017, Trialtrove reported that there were 594 trials for symptom relief and/or for the treatment, modification, or cure of NAFLD. Of these trials, one-third are industry sponsored trials (193), 47% of which are completed or terminated, while 37% are ongoing and 16% planned to initiate
Slide 11: Alert-PE
ALERT-PE For personal use only Pulmonary embolism (PE) is part of the venous thromboembolism (VTE) spectrum, which ranges from asymptomatic deep vein thrombosis (DVT) to fatal PE, and is a blockage of the pulmonary arteries in the lungs caused by blood clots6. PE is the third most common cause of de
Slide 12: Cystic Fibrosis Tool
CYSTIC FIBROSIS TOOL For personal use only Cystic Fibrosis (CF) is a serious progressive genetic disease found mainly in Caucasians that causes persistent lung infections and cumulative, progressive and irreversible lung damage that severely limits the quality and length of life of those living with
Slide 13: Expansion via Radiology Platforms Channel Partners
EXPANSION VIA RADIOLOGY PLATFORMS CHANNEL PARTNERS For personal use only
Slide 14: R&D: Imaging
For personal use only R&D: IMAGING
Slide 15: Product Improvements
PRODUCT IMPROVEMENTS For personal use only ❖ 3T CALIBRATION: Resonance Health is currently studying whether the FerriScan service can be calibrated to 3 Tesla (3T) scanners. If successful, this would also allow customers to select the FerriScan service on either 1.5 or 3T MRI machines. ❖ SHORTER ACQ
Slide 16: Liver Fibrosis Project
LIVER FIBROSIS PROJECT For personal use only ❖ NOVEL METHOD FOR FIBROSIS ASSESSMENT: The Company’s study to investigate the ability of a novel non- invasive MRI method to assess liver fibrosis is progressing well. Recruitment is now 50% complete, with the first stage of the fibrosis project expected
Slide 17: R&D: Molecular Medicine
For personal use only R&D: MOLECULAR MEDICINE
Slide 18: Antiviral Therapies Project
ANTIVIRAL THERAPIES PROJECT For personal use only While vaccination can prevent Hepatitis B, globally some 250 million people remain chronically infected, including an estimated 230,000 in Australia (of which 2 out 5 remain undiagnosed)12 . Up to 25% of people with Chronic Hepatitis B (CHB) die from
Slide 19: Liver Iron Blood Test Project
LIVER IRON BLOOD TEST PROJECT For personal use only At present, a very common blood test (serum ferritin, ‘SF’) is routinely used as a proxy for the iron status of a patient. Although SF is routinely used, it is an acute phase reactant and can be affected by the presence of many other conditions suc
Slide 20: Molecular Medicine Progress
MOLECULAR MEDICINE PROGRESS “The application of nucleic acid technology and advanced disease marker identification is changing medicine on a daily basis. In developing ASO medicines and diagnostic tools to address the global challenges of liver disease, the efforts of the Molecular Medicine R&D grou
Slide 21: References
References For personal use only 1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization. 2008 Jun;86(6):480-487. DOI: 10.2471/blt.06.036673. 2. American Society of Hematology. (n.d.). Patients – Sickle Cell Dise
Slide 22: Value Proposition
VALUE PROPOSITION For personal use only Manufacturer of regulatory Diverse R&D Pipeline cleared medical devices (SaMD) ❖ 5 Regulatory Cleared Services ❖ Artificial Intelligence ❖ Targeting FDA clearance on ❖ Imaging second AI solution, HepaFat-AI ❖ Molecular Medicine Growing Revenue Strong Balance S
Resonance Health — Shareholder Meeting (November 2020) on 6ix